N/A
N=30
Enhancing Cognitive Control in Mild Cognitive Impairment Via Non-invasive Brain Stimulation
Mild Cognitive Impairment
Bottom Line
View on ClinicalTrials.gov: NCT04647032 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
May 2023
Primary outcome: Primary: Divided Attention Performance — 9.29; 9.31 difficulty level acheived
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Transcranial alternating current stimulation (Device)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- University of California, San Francisco
- Primary completion
- Dec 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Divided Attention Performance |
10.10; 10.67 | — |
| PRIMARY Divided Attention Performance |
10.10; 10.67 | — |
| PRIMARY Sustained Attention Performance |
428; 395 | — |
| PRIMARY Sustained Attention Performance |
428; 395 | — |
| PRIMARY Working Memory Performance |
6.13; 6.50 | — |
| PRIMARY Working Memory Performance |
6.13; 6.50 | — |
| SECONDARY Instrumental Activities of Daily Living (IADL) |
4; 4 | — |
| SECONDARY Instrumental Activities of Daily Living (IADL) |
4; 4 | — |
Summary
The overall goal of this project is to improve cognitive control abilities in adults with mild cognitive impairment (MCI) through a form of non-invasive brain stimulation, transcranial alternating current stimulation (tACS).
Eligibility Criteria
Inclusion Criteria
- English speaking
- Grade 12 or more education
- Normal or corrected to normal vision and hearing
- Ability to complete cognitive tasks
- Ability to cooperate and comply with all study procedures
- Ability to tolerate tACS
- Montreal Cognitive Assessment score: 17-28
- -1 z-score on immediate memory, delayed memory, fluency, processing speed, or task switch
- Self-reported memory complaint
Exclusion Criteria
- Neurological or psychiatric disorders other than mild cognitive impairment
- Receiving investigational medications or have participated in a trial with investigational medications within last 30 days
- Family history of epilepsy
- Implanted electronic devices (e.g., pacemaker)
- Prior head trauma
- Pregnant
- IQ < 80
- Taking cholinesterase inhibitory, memantine, or psychotropic medication
- Taking anti-depressants or anti-anxiety medication
- Color blind
- Substance abuse
- Glaucoma
- Macular degeneration
- Amblyopia (lazy eye)
- Strabismus (crossed eyes)
Data sourced from ClinicalTrials.gov (NCT04647032). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.